Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk

STATUS

Recruiting
End date

Sep 30, 2024
participants needed

76
sponsor

Massachusetts General Hospital

Send

Updated on 18 February 2022

See if I qualify

body mass index

cancer

hepatitis

growth hormone

vitamin e

MRI

hepatic failure

liver disease

hepatitis b surface antigen

fatty liver

steatosis

fats

vitamin

vitamins

magnetic resonance spectroscopy

steatohepatitis

proton magnetic resonance spectroscopy

Summary

Nonalcoholic fatty liver disease (NAFLD) is common in individuals with obesity and is a significant threat to public health, because it can lead to impaired liver function and liver failure. Growth hormone is a hormone produced in the pituitary gland that helps regulate metabolism and growth. Individuals with obesity, on average, secrete less growth hormone than individuals without obesity. There are data to suggest that growth hormone may help to reduce the amount of fat in the liver, and may also reduce inflammation in the liver, both of which would be helpful to individuals with NAFLD. The purpose of this study is to investigate whether treatment with a drug called tesamorelin, which is a growth hormone releasing hormone analogue, will decrease liver fat and improve liver inflammation and scarring in obese individuals with NAFLD.

Details

Condition	Non-Alcoholic Fatty Liver Disease, Obesity, Obesity, Abdominal, Liver Fat, Fatty Liver
Treatment	Tesamorelin, Identical Placebo
Clinical Study Identifier	NCT03375788
Sponsor	Massachusetts General Hospital
Last Modified on	18 February 2022

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Men and women 18-65yo
	Body mass index (BMI) 30kg/m2, or, for participants with known steatohepatitis, BMI 25kg/m2
	Hepatic steatosis as demonstrated by either a) Grade 1+ steatosis on a liver biopsy performed within 12 months of the baseline visit, without >10% reduction in body weight or addition of medications to treat fatty liver, or b) liver fat fraction 5% on hydrogen-magnetic resonance spectroscopy (1H-MRS)
	Hepatitis C antibody and Hepatitis B surface antigen negative. Subjects without known history of Hepatitis C or Hepatitis C treatment who have a positive Hepatitis C antibody but a negative hepatitis C viral load will also be eligible
	For females 50yo, negative mammogram within 1 year of baseline
	If use of vitamin E 400 international units daily, stable dose for 6 mos
	Up to date with colon cancer screening recommended by the participant's primary care physician, using whatever methodology the primary physician recommends. This will be ascertained by self-report. (If a participant does not have a primary care physician, we will discuss that colon cancer screening is recommended, typically starting at age 50y, and refer the participant to primary care through Partners if s/he desires.)
Exclusion Criteria
	Heavy alcohol use defined as consumption of > 20 grams daily for women or > 30 grans daily for men for at least 3 consecutive months over the past 5 years assessed using the Lifetime Drinking History Questionnaire
	Known diagnosis of diabetes, use of any anti-diabetic medications (including thiazolidinediones or metformin), fasting glucose >126mg/dL, or hemoglobin A1c (HbA1c) 6.5%. Participants with stable use of metformin 6 months will be permitted if it is being used for pre-diabetes or another non-diabetes indication (e.g., PCOS)
	Use of any specific pharmacological treatments for NAFLD/nonalcoholic steatohepatitis except vitamin E
	Known cirrhosis, Child-Pugh score 7, stage 4 fibrosis on biopsy, or clinical evidence of cirrhosis or portal hypertension on imaging or exam. If a subject is not known to be cirrhotic at screen but is found to be cirrhotic based on the results of liver biopsy at baseline, this subject will be referred to a hepatologist for clinical care and will be excluded from further participation in the study
	Chronic systemic corticosteroid use in the 6 months prior to the baseline visit
	Chronic use of Actigall, methotrexate, amiodarone, or tamoxifen
	Known diagnosis of alpha-1 antitrypsin deficiency, Wilson's disease, hemochromatosis, or autoimmune hepatitis
	Use of growth hormone or growth hormone releasing hormone within the past 6 months
	Change in lipid lowering or anti-hypertensive regimen within 2 months of screening
	Hemoglobin < 10.0 g/dL or Creatinine >1.5mg/dL
	Active malignancy
	For men, history of prostate cancer or evidence of prostate malignancy by prostate specific antigen (PSA) > 5 ng/mL
	Severe chronic illness judged by the investigator to present a contraindication to participation
	History of hypopituitarism, head irradiation or any other condition known to affect the GH axis
	Use of physiologic testosterone (men) or estrogen or progesterone (women) unless stable use for a year or more prior to study entry
	Routine magnetic resonance imaging (MRI) exclusion criteria such as the presence of a pacemaker or cerebral aneurysm clip
	Weight loss surgery within 1 year before baseline. Weight loss surgery more than 1 year prior to baseline visit is permissible as long as no active weight loss (<10% decrease in weight over past 6 months)
	For women, positive urine pregnancy test (hCG), trying to achieve pregnancy, or breastfeeding
	For women able to become pregnant, unwillingness to use an acceptable form of birth control during the study
	Known hypersensitivity to tesamorelin or mannitol
	Contraindication to receiving beta-blocker or nitroglycerin (which are part of the coronary angiography)
	Significant radiation exposure, including any history of radiation therapy, or any of the following in the 12 months prior to randomization: a) more than 2 percutaneous coronary interventions; b) more than 2 myocardial perfusion studies; 3) more than 2 computed tomography angiograms
	Active consideration for a procedure or treatment that involves significant radiation exposure as defined above in the 12 months following randomization
	Not willing or able to adhere to dose schedules and required procedures per protocol
	Judged by the investigator to be inappropriate for the study for other reasons not detailed above

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

0/250

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

hepatitis b surface antigen

magnetic resonance spectroscopy

steatohepatitis

proton magnetic resonance spectroscopy

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Study Definition

Wikipedia

Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk